Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries

BACKGROUND: The recombinant tetravalent live-attenuated dengue vaccine based on the YF 17D vaccine virus backbone (CYD-TDV) demonstrated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue of any serotype from month 13 to month 25 (VCD-DENV-Any(M13→M25)) in the CYD14 (2–14-y-ol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trans R Soc Trop Med Hyg
Main Authors: Huang, Ying, Moodie, Zoe, Juraska, Michal, Fong, Youyi, Carpp, Lindsay N, Chambonneau, Laurent, Coronel, Diana L, Dayan, Gustavo H, DiazGranados, Carlos A, Gilbert, Peter B
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8245293/
https://ncbi.nlm.nih.gov/pubmed/33369671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/trstmh/traa154
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados